- Home
- SUPX vs ZYME Comparison
SUPX vs ZYME Comparison
Compare SUPX & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPX | ZYME |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2024 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SUPX | ZYME |
|---|---|---|
| Price | $17.74 | $26.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | 430.2K | ★ 1.7M |
| Earning Date | 10-24-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,596,575.00 | ★ $134,481,000.00 |
| Revenue This Year | N/A | $64.45 |
| Revenue Next Year | N/A | $67.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 23.88 | ★ 116.21 |
| 52 Week Low | $2.75 | $9.03 |
| 52 Week High | $76.50 | $28.49 |
Technical Indicators
Market Signals| Indicator | SUPX | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 30.09 | 62.08 |
| Support Level | $16.03 | $24.79 |
| Resistance Level | $21.31 | $26.46 |
| Average True Range (ATR) | 3.84 | 1.27 |
| MACD | 0.18 | -0.28 |
| Stochastic Oscillator | 21.18 | 35.60 |
Price Performance
Historical ComparisonAbout SUPX Super X AI Technology Limited Ordinary Shares
Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.